TGTX-106

N/A

Report date: 2024/06/07 17:16:07

Base Information

Drug NameTGTX-106
Drug Alias NameTSHA-106TGTX-106
ClassificationCell and gene therapy > Gene therapy > Viral vector-based gene therapy > Adeno-associated virus vector
Mechanisms of ActionRNA interferenceUbiquitin-like modifier-activating enzyme 3A stimulants
TargetsUbiquitin-like modifier-activating enzyme 3A
Therapy Area/IndicationsAngelman Syndrome
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesUniversity of Texas Southwestern Medical CenterUniversity Of North Carolina At Chapel Hill
China Registration ClassN/A

Develop Information

Active CompaniesTaysha Gene Therapies Inc
Inactive CompaniesN/A
Active IndicationsAngelman Syndrome
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A